Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine

Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax intends to have its vaccine in unit-dose vials available for distribution in the European Union for immediate release post-approval. Novavax has also filed with the U.S. Food and Drug Administration (FDA) and is working with other regulatory authorities globally on authorization or approval of its JN.1 COVID-19 vaccine. When added to vaccines, Novavax's patented saponin-based Matrix-M adjuvant enha ...